Is BPC-157 legal now? The FDA panel just voted yes

What the FDA panel actually voted on

The Pharmacy Compounding Advisory Committee met July 23 and 24 at FDA White Oak to decide whether seven peptides belong on the 503A Bulk Drug Substances List, the list that would let licensed compounding pharmacies fill a physician-written prescription under formal FDA recognition. We previewed what that hearing would decide when it was scheduled, and covered FDA staff's own recommendation against all seven after it posted on June 30.

Thursday, July 23, covered four peptides: BPC-157, KPV, TB-500, and MOTS-c. The committee voted on each and recommended all four for the compounding list. Semax, Epitalon, and emideltide (also called DSIP) were scheduled for Friday, July 24, and results from that session were not yet public as of this writing.

The vote count: 8-6, the same eight names each time

BPC-157 passed 8 votes in favor, 6 against, with one abstention. KPV passed by the identical 8-6 margin. Each substance actually got two votes, since both its free base and acetate salt forms were under separate review, and the outcomes lined up. TB-500 and MOTS-c, taken up later that afternoon, also passed, though detailed vote breakdowns for those two had not been published individually as of this writing.

What stands out is not the margin. It is who was on each side of it. Reporting from STAT found that every one of the eight newly appointed committee members, added to the panel earlier this year, voted yes on BPC-157, KPV, and TB-500. Six of those eight run or promote peptide clinics, pharmacies, or consulting businesses. The panel effectively split along the line between new appointees with a commercial stake in peptides and longer-tenured members without one.

This is exactly the conflict of interest we flagged

Back on July 19, we covered reporting that several new committee members had financial ties to the peptide industry they were about to help regulate: clinic owners, a paid peptide consultant with a large social media following, and a pharmacist whose family business compounds and sells peptides. At the time, the FDA had added independent academics to the 20-member panel in response to those concerns, and the outcome was genuinely uncertain.

It is no longer uncertain. Every flagged appointee voted the same way, on every substance, against their own agency's staff findings. That does not prove any individual vote was cast in bad faith. It does mean the story we flagged as a risk before the hearing is now the story of the hearing itself.

Why FDA staff's own scientists disagreed

The briefing documents FDA career scientists posted June 30 recommended against all seven peptides, citing the same core problems across the board: inconsistent naming and characterization between free base and acetate salt forms, thin or nonexistent human clinical trial data, and specific safety flags, including adverse event reports for BPC-157 and World Anti-Doping Agency prohibited status for MOTS-c and TB-500. None of that changed between June 30 and July 23. What changed was which body was doing the evaluating.

An advisory committee is not required to defer to staff. Committees push back on staff conclusions for legitimate scientific reasons all the time. What makes this instance different is the uniformity: eight votes, cast by members with a shared financial interest, lining up identically across four unrelated substances, against a staff recommendation that was itself uniform for the opposite reason.

TB-500 and MOTS-c passed too, with thinner human data than BPC-157

BPC-157 at least has a handful of small human studies FDA staff could point to and reject on methodological grounds. TB-500 and KPV did not. FDA staff said they found zero human studies of TB-500 for any use, in any form, and the closest evidence in the record, an in-vitro fibroblast test, actually showed the opposite of the claimed effect. MOTS-c carries the added complication of its World Anti-Doping Agency prohibited status, since it is studied partly as a performance and metabolism compound. Both passed the committee vote anyway, by what reporting describes as similar margins to BPC-157 and KPV.

So, is BPC-157 legal now? Not yet

Nothing about BPC-157's legal status changed this week. A committee recommendation is not a rule. The FDA has to propose a rule change to add BPC-157 to the 503A Bulks List, run a separate public comment period on that specific proposal, and finalize it, a process that has historically taken many months once a committee votes and carries no statutory deadline. Only after a final rule would a licensed compounding pharmacy be able to fill a physician-written BPC-157 prescription under formal FDA authorization.

BPC-157 was never FDA-approved as a finished drug, and this vote does not change that either. The online research-chemical market where most people buy BPC-157 today operates outside the compounding system entirely and is unaffected by any part of this process, whichever way the FDA ultimately rules.

What to watch next

Three things matter from here. First, whether Friday's votes on Semax, Epitalon, and emideltide follow the same 8-6 pattern or break differently, since those three peptides have thinner historical compounding use than BPC-157 and TB-500. Second, whether the FDA opens a formal rulemaking docket for the four peptides that passed, and how long that takes. Third, whether the conflict-of-interest story draws any institutional response, recusal rules, panel reconstitution, or congressional attention, given how directly this vote validated the concern. For the peptide-specific detail on what the evidence actually supports today, independent of where the regulatory process lands, see our peptide stacks guide and our breakdown of BPC-157 with a GLP-1.